Nacionalinis Vėžio Institutas

What Nacionalinis Vėžio Institutas does

Nacionalinis Vėžio Institutas (NVI) is Lithuania's national cancer research institute, established in 1931 and headquartered in Vilnius. Operating as a non-profit public legal entity since the 2025 transfer of clinical activities to VUL Santaros klinikos, NVI's core mandate is scientific research and experimental development across nine specialized laboratories covering molecular oncology, immunology, biomedical physics, genetic diagnostics, cancer epidemiology, clinical oncology, drug development, and psycho-oncology. The institute operates Lithuania's national Cancer Registry — an AI-powered information system containing 6.67M+ malignancy records since 1978, processing 20,000+ new reports annually and exposing open data via a public portal. Supporting assets include the Biobank for biological sample storage, the Open Access Center (providing spectroscopy, confocal microscopy with FLIM, and nanoparticle characterization to external researchers), and a Clinical Research Center for Phase I–III trials.

The technology stack combines proprietary nanotheranostic platforms (optical diagnostics integrated with photodynamic therapy, recognized by the 2025 Lithuanian Science Prize), NLP pipelines for unstructured medical record extraction, predictive analytics for survivor outcome modeling, and cellular immunotherapy development (dendritic cell preparations, CAR-T research, TIL analysis). Revenue mechanics are project-based and tripartite: Lithuanian state budget allocations for research operations, EU framework program grants (Horizon Europe, EU4Health, NextGenerationEU, Lithuania-Taiwan bilateral), and contracted service revenue from open-access laboratory work and commissioned research. Identified EU project inflows exceed €12M across PanCare4AYA, LATE-AYA, and the Data Management Model initiative. The institute's customer base consists of healthcare institutions, policy makers, the clinical research community, and indirectly cancer patients via clinical trials; student internships and academic partnerships round out the stakeholder set. No commercial pricing is publicly disclosed, consistent with NVI's public-sector status.

Name

Nacionalinis Vėžio Institutas

Legal name

Nacionalinis Vėžio Institutas

Website

https://nvi.lt

Company type

Private

Founded year

1931

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Nacionalinis Vėžio Institutas is Lithuania's national cancer research institute, operating the state-mandated Cancer Registry (6.67M+ records since 1978) and nine specialized scientific laboratories, serving public health authorities, clinical researchers, and cancer patients across Europe.

Ownership category

akta.pro rank

Product category

Cancer Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Services-Health Services (8000), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Research & Trial Central Laboratories (HLAFAMAL)

akta.pro secondary industry

Medical Oncology (HLAKAFAB)

Keywords

• Cancer research services
• Oncology epidemiology
• Cancer registry data
• Biomedical research laboratory
• Clinical trial coordination

Headquarters

HQ city

Vilnius

HQ country

Lithuania

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

1. State Budget Funding: As a public non-profit institution, NVI receives government funding for scientific research and experimental development activities aligned with oncology and related fields.
2. EU Project Funding: NVI participates in multiple EU-funded projects including Horizon Europe, NextGenerationEU, EU4Health, and bilateral Lithuania-Taiwan scientific cooperation programs.
3. Service Revenues: The institute generates revenue from open access center services, commissioned research, and potentially clinical trials conducted in partnership with pharmaceutical companies.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Nacionalinis Vėžio Institutas is a publicly funded, non-profit research institution conducting scientific research and experimental development in oncology across multiple specialized laboratories. Its core deliverable is the operation of Lithuania's national Cancer Registry — an AI-enabled information system tracking over 6.67 million malignancy cases since 1978 — alongside commissioned cancer research, biobanking services, Open Access Center laboratory capabilities (spectroscopy, confocal microscopy, FLIM), and clinical trial support in partnership with Vilnius University Hospital Santaros klinikos.

Product overview

Nacionalinis Vėžio Institutas operates as a public medical research institution offering a portfolio of specialized cancer research services and information systems. The primary product is the Cancer Registry Information System (Vėžio registro informacinė sistema) — an AI-powered digital platform that provides open data access for cancer monitoring and epidemiology across Lithuania, processing 6.6 million malignancy records. Supporting services include the Open Access Center providing microscopy, spectroscopy, and imaging services to external researchers, and nine specialized scientific research laboratories covering cancer epidemiology, immunology, molecular oncology, oncogenetics, clinical oncology, drug development, biomedical physics, and psycho-oncology. The institution also maintains the Biobank for biological sample storage and operates the Clinical Research Center for Phase I-III trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer Registry Information System (Vėžio registro informacinė sistema) AI-powered information system providing open data access for cancer monitoring and epidemiology in Lithuania. The system processes medical records to extract cancer staging, tumor differentiation degrees, and treatment information using natural language processing, with 6.6 million+ malignancy records since 1978.
• Open Access Center (Atvirosios prieigos centras) Centralized facility offering advanced microscopy, spectroscopy, and imaging services to internal and external researchers for biomedical research applications, including spectroscopy, confocal microscopy with FLIM, nanoparticle characterization, and in vivo imaging.

Quantifiable outcome

• 20,000+ new cancer reports processed annually
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

14 partnerships are on record, tiered core, major and supporting.

• Nacionalinis Vėžio Centras (NVC)coreStrategic or Co-development Partner · 2 July 2026NVI and NVC signed a trilateral cooperation declaration with IFPA for advancing personalized medicine in Lithuania. The partnership aims to accelerate personalized medicine implementation, improve health data management, develop digital solutions and biobank infrastructure, strengthen international visibility (OECI, BBMRI-ERIC), and contribute to sustainable and innovative health system creation. Clinical activities were transferred from NVI to NVC Santaros klinikos in 2025.
• Inovatyvios Farmacijos Pramonės Asociacija (IFPA)coreStrategic or Co-development Partner · 2 July 2026Tripartite cooperation declaration signed with NVI and NVC. Partnership focuses on personalized medicine implementation, clinical trial expansion, early accessibility programs, advanced pricing and reimbursement policy development, and innovative solutions for health system efficiency. IFPA represents innovative pharmaceutical industry manufacturers supporting modern and sustainable healthcare.
• Universidad Politécnica de Madrid (UPM)coreStrategic or Co-development Partner · 1 June 2025LATE-AYA project main coordinator. Project focuses on AI-driven digital phenotyping and non-invasive holistic approach for understanding and addressing late effects of cancer treatment in AYA survivors. Project number 101214326, EU contribution €6,239,687.50, duration 60 months.
• The Prinses Máxima Centrum voor Kinderoncologie (PMC), NetherlandscoreStrategic or Co-development Partner · 1 April 2025PanCare4AYA project main coordinator. 29 partners from 14 countries collaborating on adolescent and young adult cancer survivorship care guidelines and screening programs. Project duration 5 years, EU funding €5,770,234.25.
• Vilnius University Hospital Santaros KlinikoscoreStrategic or Co-development Partner · 1 April 2025NVI and Santaros klinikos partner in PanCare4AYA project for survivorship care improvement. As of 2025, clinical activities were transferred from NVI to this institution. Lithuanian partners contribute clinical expertise and patient recruitment for the AYA Cancer Survivor Screen program.
• Valstybės Skaitmeninių Sprendimų AgentūramajorStrategic or Co-development Partner · 11 October 2022Collaboration on 'Data Management Model Creation' project (Nr. 02-009-P-0001) funded by 'New Generation Lithuania' plan. Project aims to develop state information resources data architecture management infrastructure, data governance model, and centralized technical tools for 376 state information systems. Project value €16.27M, NVI portion €24,082.98.
• Université Laval National Research Institute (Canada)supportingTechnology or IntegrationScientific collaboration through Biomedical Physics Open Access Center and international research programs. Focus areas include energy, materials and telecommunications research.
• University of Toronto - Faculty of Physics and Physical Chemistry (Canada)supportingTechnology or IntegrationInternational research collaboration in biophysics and physical chemistry through NANOTECMEC and other programs.
• Oregon State University - Department of Chemistry (USA)supportingTechnology or IntegrationCollaboration with researcher Artiom Skripka on nanomedicine and theranostics research.
• National Yang Ming Chiao Tung University (Taiwan)majorStrategic or Co-development PartnerLithuania-Taiwan bilateral cooperation on 'Targeted anti-cancer cell therapy using multifunctional nanoplatform and mesenchymal stem cells' project (Nr. P-LT-TW-24-17). Taiwan partners synthesize dendrimeric nanoparticles with fluorescent labeling and chemotherapy drug integration.
• Loyola University Chicago (USA)supportingStrategic or Co-development PartnerImmunology laboratory collaboration on cancer immunotherapy research.
• CITIM Cancer Immunotherapy and Immunomonitoring ConsortiumsupportingStrategic or Co-development PartnerInternational consortium collaboration on cancer immunotherapy development.
• UAB FrocethsupportingTechnology or IntegrationBusiness partner collaboration on immunomodeling for infertility diagnostics and treatment (2019-2022 project).
• Inovacinių Alergologijos CentrassupportingTechnology or IntegrationCollaboration on joint science-business projects for immunomodeling research.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Karolinska Institute: Sweden's national medical university with large-scale cancer epidemiology, registry-style research, and clinical-translation programs. Highly comparable to NVI as a publicly funded cancer-research powerhouse combining registries, labs, and EU-funded consortia activity.
• Netherlands Cancer Institute (NKI): Dutch comprehensive cancer research and treatment center combining fundamental research with clinical care. Comparable to NVI's historical integrated model and a key PanCare4AYA coordinator, making it both a peer and a partner.
• Spanish National Cancer Research Centre (CNIO): Spain's national cancer research center running molecular oncology, clinical research, and EU-funded programs. Closely mirrors NVI's structure as a publicly funded, multi-lab cancer research institute without inpatient hospital functions.

Broad incumbents

• German Cancer Research Center (DKFZ): Germany's national biomedical research agency with broad oncology, immunotherapy, and AI-imaging programs. A larger-scale, broader-scope counterpart to NVI; operates at a higher funding tier but pursues the same mission of national cancer research leadership.
• International Agency for Research on Cancer (IARC): WHO's specialized cancer research agency focused on epidemiology, registry methodology, and global cancer monitoring. Directly comparable to NVI's Cancer Registry and cancer-epidemiology laboratory mandate.
• Institut Gustave Roussy: Leading European comprehensive cancer center combining research, treatment, and education. Comparable to NVI's pre-2025 integrated model and to its current research ambitions in immunotherapy and precision oncology.
• National Cancer Institute (NCI, USA): U.S. federal agency for cancer research and training, the largest cancer research funder globally. Comparable to NVI as a public-sector cancer research authority with national registry, grant-making, and translational mandates — but at vastly larger scale.

Others

• European Organization for Research and Treatment of Cancer (EORTC): Pan-European clinical cancer research organization running multi-country trials and translational research. Comparable to NVI's role as a Lithuanian partner in EU oncology consortia (e.g., PanCare4AYA, INTERACT-EUROPE 100) and as a clinical-trial operator.

Regional players

• Masaryk Memorial Cancer Institute (Czech Republic): Czech national cancer research and treatment center. A Central European peer running cancer epidemiology, clinical research, and translational programs within a publicly funded structure similar to NVI.
• Maria Skłodowska-Curie National Research Institute of Oncology (Poland): Poland's national oncology research and treatment institute. A direct Central/Eastern European peer in mandate, scale, and EU grant participation — the closest regional comparator to NVI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php?id=61582047926851
• LinkedInlinkedin.com/company/nacionalinis-vezio-institutas

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nacionalinis Vėžio Institutas